Ato Sugiyama, Tai Hato, Hiroaki Kashimada, Masatoshi Yamaguchi, Yoshiaki Inoue, Kohei Aoki, Hiroki Fukuda, Mitsuo Nakayama, Morihiro Higashi, Mitsutomo Kohno
{"title":"Histopathological Correlation Between High Endothelial Venule Neogenesis and the Tumor Microenvironment in Lung Adenocarcinoma.","authors":"Ato Sugiyama, Tai Hato, Hiroaki Kashimada, Masatoshi Yamaguchi, Yoshiaki Inoue, Kohei Aoki, Hiroki Fukuda, Mitsuo Nakayama, Morihiro Higashi, Mitsutomo Kohno","doi":"10.21873/invivo.13754","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>The dynamic interplay between cancer cells and the microenvironment involves a wide range of intricate relationships that evolve during different stages of tumor progression. Recent attention has focused on high endothelial venules (HEVs), specialized endothelial cells in tumors with a unique cuboidal shape similar to those in lymph nodes. Previous animal studies have shown that normalization of tumor angiogenesis through anti-VEGFR2 therapy promotes HEV formation. However, few reports exist regarding the relationship between HEVs and preexisting blood vessels or interstitial fibers. In this study, we histologically examined whether tumor vascular structure correlates with HEV neogenesis.</p><p><strong>Patients and methods: </strong>A total of 109 patients with pathological stage I lung adenocarcinoma who had undergone curative lung resection at our Institute between 2012 and 2016 were included. HEVs were identified by anti-peripheral node addressin (PNAd) staining. Immunostaining and Elastica-Masson-Goldner staining were performed on tumor sections and quantified.</p><p><strong>Results: </strong>PNAd-positive cells were identified in 102 (93.6%) patients. Nearly all PNAd-positive cells were located within or near immune cell clusters. We investigated the correlation between microvessel structures or interstitial fibers and the number/density of PNAd-positive vessels, but no significant correlation was found. Since PNAd-positive cells were concentrated in immune cell aggregates, we focused our analysis specifically on these regions. Immune cell aggregates with abundant PNAd-positive vessels had a greater microvessel density along with by rich collagen fiber production, and displayed a more mature morphological phenotype of HEVs.</p><p><strong>Conclusion: </strong>The generation of PNAd-positive cells in tumors is governed by an angiogenetic mechanism distinct from that of broader tumor microenvironment. Furthermore, the accumulation of immune cells is associated with increased HEV maturation.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"38 6","pages":"2752-2760"},"PeriodicalIF":1.8000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11535917/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.13754","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: The dynamic interplay between cancer cells and the microenvironment involves a wide range of intricate relationships that evolve during different stages of tumor progression. Recent attention has focused on high endothelial venules (HEVs), specialized endothelial cells in tumors with a unique cuboidal shape similar to those in lymph nodes. Previous animal studies have shown that normalization of tumor angiogenesis through anti-VEGFR2 therapy promotes HEV formation. However, few reports exist regarding the relationship between HEVs and preexisting blood vessels or interstitial fibers. In this study, we histologically examined whether tumor vascular structure correlates with HEV neogenesis.
Patients and methods: A total of 109 patients with pathological stage I lung adenocarcinoma who had undergone curative lung resection at our Institute between 2012 and 2016 were included. HEVs were identified by anti-peripheral node addressin (PNAd) staining. Immunostaining and Elastica-Masson-Goldner staining were performed on tumor sections and quantified.
Results: PNAd-positive cells were identified in 102 (93.6%) patients. Nearly all PNAd-positive cells were located within or near immune cell clusters. We investigated the correlation between microvessel structures or interstitial fibers and the number/density of PNAd-positive vessels, but no significant correlation was found. Since PNAd-positive cells were concentrated in immune cell aggregates, we focused our analysis specifically on these regions. Immune cell aggregates with abundant PNAd-positive vessels had a greater microvessel density along with by rich collagen fiber production, and displayed a more mature morphological phenotype of HEVs.
Conclusion: The generation of PNAd-positive cells in tumors is governed by an angiogenetic mechanism distinct from that of broader tumor microenvironment. Furthermore, the accumulation of immune cells is associated with increased HEV maturation.
背景/目的:癌细胞与微环境之间的动态相互作用涉及肿瘤进展不同阶段演变的各种错综复杂的关系。高内皮细胞静脉(HEVs)是肿瘤中的特化内皮细胞,其独特的立方体形状与淋巴结中的内皮细胞相似。之前的动物研究表明,通过抗血管内皮生长因子受体 2(VEGFR2)疗法使肿瘤血管生成正常化可促进 HEV 的形成。然而,有关 HEV 与原有血管或间质纤维之间关系的报道却很少。在本研究中,我们从组织学角度研究了肿瘤血管结构是否与 HEV 新生有关:纳入2012年至2016年期间在我院接受肺癌根治性切除术的病理分期为I期的肺腺癌患者共109例。通过抗外周结节地址素(PNAd)染色确定HEV。对肿瘤切片进行免疫染色和Elastica-Masson-Goldner染色,并进行量化:结果:102 例(93.6%)患者中发现了 PNAd 阳性细胞。几乎所有 PNAd 阳性细胞都位于免疫细胞簇内或附近。我们研究了微血管结构或间质纤维与 PNAd 阳性血管数量/密度之间的相关性,但未发现显著的相关性。由于 PNAd 阳性细胞主要集中在免疫细胞聚集区,我们将分析重点特别放在了这些区域。具有大量 PNAd 阳性血管的免疫细胞聚集区具有更高的微血管密度,并产生丰富的胶原纤维,显示出更成熟的 HEV 形态表型:结论:肿瘤中 PNAd 阳性细胞的生成受血管生成机制的支配,与更广泛的肿瘤微环境不同。此外,免疫细胞的聚集与 HEV 成熟度的增加有关。
期刊介绍:
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.